Maravai LifeSciences

Maravai LifeSciences, a US-based company in the research and development services industry, reported a total of approximately 75.2 million kg CO2e in emissions for 2024. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions.

For the 2024 reporting year, Scope 1 emissions were approximately 862,580 kg CO2e, and Scope 2 emissions (market-based) were about 2,208,570 kg CO2e. The most significant portion of Maravai's reported emissions in 2024 came from Scope 3, with purchased goods and services accounting for approximately 56,213,130 kg CO2e. Other notable Scope 3 categories for 2024 included capital goods at about 10,027,390 kg CO2e, and business travel at approximately 3,943,670 kg CO2e.

In 2023, the company's total emissions were approximately 13.1 million kg CO2e. Scope 1 emissions were about 736,590 kg CO2e, and Scope 2 emissions (market-based) were approximately 1,993,000 kg CO2e. Scope 3 emissions in 2023 were led by capital goods at about 10,572,000 kg CO2e and purchased goods and services at approximately 8,002,000 kg CO2e.

In terms of climate commitments, Maravai LifeSciences has committed to the Science Based Targets initiative (SBTi) and is also committed to net-zero emissions, with a target year to be determined. Their climate initiatives are cascaded from Maravai LifeSciences Holdings, Inc., with a cascade level of 0. For 2022, Scope 1 emissions were reported at approximately 377,000 kg CO2e, and Scope 2 emissions (market-based) were about 1,309,000 kg CO2e. Scope 3 emissions data was not fully disclosed for 2022. In 2021, Scope 1 emissions were approximately 330,000 kg CO2e, and Scope 2 emissions (market-based) were about 1,103,000 kg CO2e. Scope 3 emissions were not fully disclosed for 2021.